Benefits
PCOS symptom improvement
Restores ovarian function, reduces androgen levels (testosterone, DHEA-S), and improves menstrual regularity in women with PCOS. Ovulation frequency rises in trials, but pooled data show no significant effect on pregnancy rates. In small trials at 4 g/day, myo-inositol produced changes in insulin sensitivity and menstrual regularity similar to metformin, with fewer gastrointestinal complaints. The 40:1 myo:D-chiro ratio is preferred over myo-inositol alone for the full PCOS effect profile.
Modest BMI change (secondary to insulin sensitivity)
Inositol supplementation produces modest but consistent BMI reductions (approximately 0.4 kg/m² average), with the strongest effects in women with PCOS and overweight/obese individuals. Reported BMI reductions are small (on the order of 0.4 kg/m2) and appear as a secondary effect of improved insulin sensitivity rather than a direct weight-loss action. Mechanism centers on restoring insulin signaling via IPG second messengers.
Insulin sensitivity and metabolic markers
Inositol is a structural component of insulin secondary messenger molecules (IPGs — inositol phosphoglycans). Supplementation improves insulin receptor signaling, reducing fasting glucose, fasting insulin, HOMA-IR (insulin resistance index), and other metabolic syndrome markers. Particularly relevant for individuals with insulin resistance who don't yet meet diagnostic criteria for type 2 diabetes.
Mental health and mood support
High-dose myo-inositol (12-18 g/day) has been studied in small trials for OCD, panic disorder, and depression, in some cases producing symptom changes similar to an SSRI comparator with fewer side effects. These trials are small, old, and preliminary. Acts as a second messenger in serotonin and dopamine signal transduction pathways. Therapeutic doses are much higher than the metabolic doses (2-4 g/day for PCOS), so this is a distinct application.
Ovarian response in assisted reproduction
Some IVF trials report better oocyte maturation and lower FSH dosing with myo-inositol pre-treatment, but the trials are small and inconsistent. Independent Cochrane reviews rate this evidence as low to very low quality and are uncertain whether myo-inositol improves live birth or clinical pregnancy rates.
Glucose regulation in higher-risk pregnancy
In pooled trials of pregnant women at higher risk of glucose problems (family history, obesity, PCOS history), 4 g/day myo-inositol was associated with a lower rate of gestational diabetes at 24 to 28 week screening. Most of these trials come from a single Italian research group and independent reviewers rate their quality as low, so the size of any real effect is uncertain.
Mechanism of action
Insulin signaling second messenger
Inositol phosphoglycans (IPGs) are intracellular mediators of insulin receptor signaling. They activate pyruvate dehydrogenase and other insulin-responsive enzymes, improving glucose utilization in muscle, liver, and adipose tissue. This mechanism explains inositol's parallel effects on insulin sensitivity, metabolic markers, and PCOS — all of which share underlying insulin resistance biology.
Phospholipid membrane component
Phosphatidylinositol and its phosphorylated forms (PIP, PIP2, PIP3) are essential membrane lipids serving as docking sites for signaling proteins and precursors to second messengers DAG (diacylglycerol) and IP3 (inositol trisphosphate). Roughly 5% of all cell membrane phospholipid mass is inositol-based.
Serotonin and dopamine receptor coupling
IP3 (inositol trisphosphate) is a key second messenger for serotonin (5-HT2) and dopamine receptors. Inositol depletion reduces signal transduction at these receptors, providing the theoretical basis for inositol in mood disorders. High-dose supplementation (12-18 g/day) appears necessary to meaningfully raise CNS inositol levels — much higher than the metabolic-effect dose.
40:1 myo:D-chiro ratio for PCOS
In healthy women, plasma myo-inositol and D-chiro-inositol exist at approximately a 40:1 ratio; women with PCOS show altered ratios favoring D-chiro accumulation in ovaries (the 'D-chiro paradox'). Supplementing the physiological 40:1 ratio restores normal cellular signaling, while D-chiro-inositol alone or excess D-chiro can worsen ovarian function in PCOS.
Clinical trials
Randomized trial comparing myo-inositol (4 g/day) with metformin (1,500 mg/day) in 50 women with PCOS and insulin resistance over 6 months. Outcomes: BMI, insulin sensitivity, menstrual regularity. (Fruzzetti 2017, Gynecol Endocrinol)
50 women with PCOS and insulin resistance. 6-month intervention.
Both treatments lowered BMI and improved insulin sensitivity and menstrual regularity, with no significant difference between them, and myo-inositol caused fewer gastrointestinal complaints. This is a single small trial; myo-inositol is typically combined with D-chiro-inositol in a 40:1 ratio.
Double-blind crossover clinical trial of inositol (18 g/day) vs fluvoxamine (150 mg/day) in 20 patients with panic disorder for 4 weeks each. (J Clin Psychopharmacol)
20 panic disorder patients. Crossover.
Over one month each, inositol and fluvoxamine produced similar reductions in panic frequency, anxiety, and global clinical impression. Inositol had significantly fewer side effects (no nausea, fatigue, sexual dysfunction). Critical dose context: 18 g/day is a very high dose (common psychiatric inositol research has used 12-18 g/day for OCD, depression, panic). Most consumer inositol products provide 500-2,000 mg — far below psychiatric research doses. Modern panic disorder treatment typically uses SSRIs/SNRIs as first-line. Inositol at very high doses may have niche role for treatment-resistant cases under psychiatric supervision.
Multiple randomized controlled trials evaluating 4 g/day myo-inositol starting in the first or second trimester for prevention of gestational diabetes in high-risk pregnant women (family history of type 2 diabetes, obesity, PCOS history). Trials predominantly conducted in Italian obstetric centers; outcomes assessed at standard gestational diabetes screening (24-28 weeks).
Pregnant women at high risk for gestational diabetes. Multi-trimester intervention from first/second trimester through delivery.
Across multiple clinical trials, 4 g/day myo-inositol supplementation reduced gestational diabetes incidence by approximately 50% vs placebo in high-risk populations. Effect most pronounced when started in the first trimester. Also associated with reduced fetal macrosomia (excess birth weight) and reduced cesarean delivery rates. No safety concerns identified in pregnancy.